Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 15
2003 16
2004 5
2005 10
2006 18
2007 15
2008 15
2009 15
2010 19
2011 15
2012 16
2013 26
2014 18
2015 21
2016 18
2017 14
2018 11
2019 10
2020 11
2021 10
2022 13
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH. Lanz TV, et al. Among authors: steinman l. Nature. 2022 Mar;603(7900):321-327. doi: 10.1038/s41586-022-04432-7. Epub 2022 Jan 24. Nature. 2022. PMID: 35073561 Free PMC article.
Epstein-Barr virus and multiple sclerosis.
Robinson WH, Steinman L. Robinson WH, et al. Among authors: steinman l. Science. 2022 Jan 21;375(6578):264-265. doi: 10.1126/science.abm7930. Epub 2022 Jan 13. Science. 2022. PMID: 35025606 Free article.
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Bar-Or A, et al. Among authors: steinman l. Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17. Trends Mol Med. 2020. PMID: 31862243 Free PMC article. Review.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: steinman l. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity.
Sagan SA, Moinfar Z, Moseley CE, Dandekar R, Spencer CM, Verkman AS, Ottersen OP, Sobel RA, Sidney J, Sette A, Anderson MS, Steinman L, Wilson MR, Sabatino JJ Jr, Zamvil SS. Sagan SA, et al. Among authors: steinman l. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2306572120. doi: 10.1073/pnas.2306572120. Epub 2023 Jul 18. Proc Natl Acad Sci U S A. 2023. PMID: 37463205 Free PMC article.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
307 results